Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Chronic myeloid leukemia in 2007.

Chronic myeloid leukemia in 2007. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Chronic myeloid leukemia in 2007. Abstract Text:

    jolynn sessionsJolynn Sessions,jolynn sessionsJolynn Sessions,

    PURPOSE: Chronic myeloid leukemia (CML), a hematopoietic stem cell cancer representing 15-20% of adult leukemias, is discussed. Epidemiology, staging biology, and monitoring techniques are reviewed. SUMMARY: CML is a myeloproliferative disorder that affects all lineages of hematopoiesis. Final confirmation of CML comes with detection of the Philadelphia Chromosome (Ph) or BCR-ABL transcripts. The disease presents in one of three phases: chronic phase, accelerated phase, or blast crisis. Progression from chronic phase to accelerated phase usually involves the accumulation of additional cytogenetic aberrations and the arising of resistance to therapy. Although at one point mortality associated with CML was high, new kinase inhibitor therapies have markedly extended the life-span of these patients. These inhibitors were derived through the initial observation of the association of the Ph with CML and the eventual identification of the BCR-ABL oncogene which arises from this translocation. Analysis of the mechanism by which BCR-ABL transforms cells identified this protein as a tyrosine kinase and led to the targeting of this activity. The majority of patients present in chronic phase, which is where these kinase inhibitors have their greatest efficacy. Monitoring of disease progression is of critical importance as the prognosis drops significantly for patients with advanced disease. Blood counts, cytogenetics, and polymerase chain reaction (PCR) are currently used to assess disease. Blood counts are inexpensive but lack sensitivity. Cytogenetic karyotyping while requiring specialized training provides evidence of clonal evolution. Quantitative PCR is capable of tremendous sensitivity making it well suited for assessing response to therapy and the early detection of therapy failures. CONCLUSION: Our understanding of BCR-ABL has allowed the development of therapies, which may keep patients with CML in chronic phase indefinitely. This has created a situation in which patient monitoring is essential for detecting changes in the status of CML. The tests described here provide a comprehensive assessment of disease status allowing for effective patient management.

    Chronic myeloid leukemia in 2007. Publishing Authors By Initials

    j sessionsJ Sessions,j sessionsJ Sessions,

    For similar diagnosis: diagnostic techniques and procedures: neoplasm staging research abstracts see: diagnosis: diagnostic techniques and procedures: neoplasm staging research

    PUBMED ID PMID:

    MEDLINE DATE:

    Chronic myeloid leukemia in 2007. Journal Published:

    PUBLICATION TYPE: Review

    Journal: American journal of health-system pharmacy : AJHP

    VOLUME: 64

    Page Numbers: S4-9

    Journal Abbreviation:

    ISSN: 1535-2900

    DAY: 15

    MONTH: Dec

    YEAR: 2007

    Chronic myeloid leukemia in 2007. Information

    Number of References: 13

    LANGUAGE: eng

    NlmUniqueID: 9503023

    Chronic myeloid leukemia in 2007. Keywords Mesh Terms:

    KEYWORDS: Neoplasm Staging

    MESH TERMS: therapy

    Chemical & Substance for Abstract: Chronic myeloid leukemia in 2007. Information

    Substance Name: Antineoplastic Agents

    Registry Number: 0

    Grant and Affiliation Information for Chronic myeloid leukemia in 2007.

    AFFILIATION: Hematology/Oncology, Emory University Hospital, 1364 Clifton Road, NE, Atlanta, GA 30322, USA. jolynn_sessions@emoryhealthcare.org

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Am J Health Syst Pharm

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Chronic myeloid leukemia in 2007 Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News